摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

di-p-tolyl phenoxycarbonylphosphonate | 74270-17-0

中文名称
——
中文别名
——
英文名称
di-p-tolyl phenoxycarbonylphosphonate
英文别名
Phosphinecarboxylic acid, bis(4-methylphenoxy)-, phenyl ester, oxide;phenyl bis(4-methylphenoxy)phosphorylformate
di-p-tolyl phenoxycarbonylphosphonate化学式
CAS
74270-17-0
化学式
C21H19O5P
mdl
——
分子量
382.353
InChiKey
IORAAQDUDVGXSM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    27
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    61.8
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    NOREN, J. O.;HELGSTRAND, E.;JOHANSSON, N. G.;MISIORNY, A.;STENING, G., J. MED. CHEM., 1983, 26, N 2, 264-270
    摘要:
    DOI:
  • 作为产物:
    参考文献:
    名称:
    Phosphonoformic acid esters
    摘要:
    式##STR1##的化合物,其中R.sub.1、R.sub.2和R.sub.3相同或不同,且每个均选自由氢和苯基组成的群,该群的式为##STR2##,其中R.sub.4和R.sub.5相同或不同,每个均选自由氢、卤素、具有1、2或3个碳原子的烷基、具有1、2或3个碳原子的烷氧基、具有2-7个碳原子的烷氧羰基;和具有2-7个碳原子的烷基羰基;或者R.sub.4和R.sub.5一起形成直链饱和的具有3或4个碳原子的烷基链,并与相邻位置即苯环中的2,3-或3,4-相连;前提是当R.sub.3为H时,R.sub.1和R.sub.2中的一个是式II的苯基;以及其生理上可接受的盐和光学异构体;制备这些化合物的方法,含有它们的药物组合物,以及它们的药用。
    公开号:
    US04372894A1
点击查看最新优质反应信息

文献信息

  • Phosphonoformic acid esters
    申请人:Astra Lakemedel Aktiebolag
    公开号:US04372894A1
    公开(公告)日:1983-02-08
    A compound of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different, and each is selected from the group consisting of hydrogen and phenyl groups of the formula ##STR2## wherein R.sub.4 and R.sub.5 are the same or different and each is selected from the group consisting of hydrogen, halogen, alkyl having 1, 2, or 3 carbon atoms, alkoxy having 1, 2, or 3 carbon atoms, alkoxycarbonyl having 2-7 carbon atoms; and alkylcarbonyl groups having 2-7 carbon atoms; or R.sub.4 and R.sub.5 together from a straight saturated alkylene chain having 3 or 4 carbon atoms and being bound to adjacent positions, i.e. 2,3- or 3,4- in the phenyl ring; provided that one of R.sub.1 and R.sub.2 is a phenyl group of the formula II when R.sub.3 is H; and physiologically acceptable salts and optical isomers thereof; methods for preparation of the compounds, pharmaceutical compositions containing them, and their medicinal use.
    式##STR1##的化合物,其中R.sub.1、R.sub.2和R.sub.3相同或不同,且每个均选自由氢和苯基组成的群,该群的式为##STR2##,其中R.sub.4和R.sub.5相同或不同,每个均选自由氢、卤素、具有1、2或3个碳原子的烷基、具有1、2或3个碳原子的烷氧基、具有2-7个碳原子的烷氧羰基;和具有2-7个碳原子的烷基羰基;或者R.sub.4和R.sub.5一起形成直链饱和的具有3或4个碳原子的烷基链,并与相邻位置即苯环中的2,3-或3,4-相连;前提是当R.sub.3为H时,R.sub.1和R.sub.2中的一个是式II的苯基;以及其生理上可接受的盐和光学异构体;制备这些化合物的方法,含有它们的药物组合物,以及它们的药用。
  • Aromatic derivatives of phosphonoformic acid, processes for their preparation, pharmaceutical compositions containing them and their use for combating virus infections
    申请人:Astra Läkemedel Aktiebolag
    公开号:EP0003275A1
    公开(公告)日:1979-08-08
    A compound of the formula wherein R,, R2 and R3 are the same or different, and each is selected from the group consisting of hydrogen and phenyl groups of the formula wherein R4 and R5 are the same or different and each is. selected from the group consisting of hydrogen, halogen, alkyl having 1; 2, or 3 carbon atoms, alkoxy having 7,2. or 3 carbon atoms, alkoxycarbonyl having 2-7 carbon atoms; and alkylcarbonyl groups having 2-7 carbon atoms; or R4 and R5 together form a straight saturated alkylene chain having 3 or 4 carbon atoms and being bound to adjacent positions, i.e. 2,3- or 3,4- in the phenyl ring; provided that one of R1 and R2 is a phenyl group of the formula II when R3 is H; and physiologically acceptable salts and optical isomers thereof; methods for preparation of the compounds, pharmaceutical compositions containing them, and their medicinal use.
    式中的化合物 其中 R、R2 和 R3 相同或不同,且各自选自由氢和式中的苯基组成的组 其中 R4 和 R5 相同或不同,且各自选自由氢、卤素、具有 1;2 或 3 个碳原子的烷基、具有 7、2. 或 3 个碳原子的烷氧基、具有 2-7 个碳原子的烷氧羰基;以及具有 2-7 个碳原子的烷基羰基组成的组;或 R4 和 R5 共同形成具有 3 或 4 个碳原子的直饱和亚烷基链,并与相邻位置结合,即即苯基环中的2,3-或3,4-;条件是当R3为H时,R1和R2中的一个是式II的苯基;以及它们的生理上可接受的盐和光学异构体;化合物的制备方法、含有它们的药物组合物及其药用用途。
  • Nonaqueous electrolyte solution, electricity storage device using same, and phosphonoformic acid compound used in same
    申请人:UBE INDUSTRIES, LTD.
    公开号:US10374256B2
    公开(公告)日:2019-08-06
    The present invention provides a nonaqueous electrolytic solution capable of suppressing worsening of heat stability of a negative electrode and improving safety of an energy storage device while maintaining high-load charging and discharging cycle properties at a high temperature, an energy storage device using the same, and a phosphonoformic acid compound to be used for the same. The nonaqueous electrolytic solution having an electrolyte salt dissolved in a nonaqueous solvent contains 0.001 to 5% by mass of at least one selected from a phosphonoformic acid compound having at least one carbon-carbon unsaturated bond, which is represented by the following general formula (I), and a phosphonoformic acid compound having a carbon-carbon unsaturated bond or two phosphonocarbonyl groups, which is represented by the following general formula (II). In the formula (I), each of R1 to R3 is an aliphatic organic group, provided that at least one of R1 to R3 represents a carbon-carbon unsaturated bond-containing aliphatic organic group. In the formula (II), each of R4 and R5 represents an alkyl group, a cycloalkyl group, or an aryl group, and R4 and R5 may be bonded to each other to form a ring structure. m represents 1 or 2; when m is 1, then R6 represents an aryl group; when m is 2, then R6 represents an alkylene group, an alkenylene group, or an alkynylene group; and a part of hydrogen atoms of R4 to R6 may be substituted with a halogen atom.
    本发明提供了一种在高温下保持高负荷充放电循环特性的同时,能够抑制负极热稳定性恶化并提高储能装置安全性的非水性电解溶液、使用该溶液的储能装置以及用于该溶液的膦甲酸化合物。具有溶解在非水溶剂中的电解质盐的非水电解溶液含有 0.001%至 5%(以质量计)的至少一种选自具有至少一个碳碳不饱和键的膦甲酸化合物(由以下通式 (I) 表示)和具有一个碳碳不饱和键或两个膦酰基的膦甲酸化合物(由以下通式 (II) 表示)。 在式 (I) 中,R1 至 R3 中的每一个都是脂肪族有机基团,条件是 R1 至 R3 中至少有一个代表含碳碳不饱和键的脂肪族有机基团。 在式 (II) 中,R4 和 R5 各自代表烷基、环烷基或芳基,且 R4 和 R5 可相互键合以形成环状结构。m 代表 1 或 2;当 m 为 1 时,则 R6 代表芳基;当 m 为 2 时,则 R6 代表亚烷基、亚烯基或亚炔基;且 R4 至 R6 的部分氢原子可被卤原子取代。
  • NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHONOFORMIC ACID COMPOUND USED IN SAME
    申请人:UBE INDUSTRIES, LTD
    公开号:US20160315351A1
    公开(公告)日:2016-10-27
    The present invention provides a nonaqueous electrolytic solution capable of suppressing worsening of heat stability of a negative electrode and improving safety of an energy storage device while maintaining high-load charging and discharging cycle properties at a high temperature, an energy storage device using the same, and a phosphonoformic acid compound to be used for the same. The nonaqueous electrolytic solution having an electrolyte salt dissolved in a nonaqueous solvent contains 0.001 to 5% by mass of at least one selected from a phosphonoformic acid compound having at least one carbon-carbon unsaturated bond, which is represented by the following general formula (I), and a phosphonoformic acid compound having a carbon-carbon unsaturated bond or two phosphonocarbonyl groups, which is represented by the following general formula (II). In the formula (I), each of R 1 to R 3 is an aliphatic organic group, provided that at least one of R 1 to R 3 represents a carbon-carbon unsaturated bond-containing aliphatic organic group. In the formula (II), each of R 4 and R 5 represents an alkyl group, a cycloalkyl group, or an aryl group, and R 4 and R 5 may be bonded to each other to form a ring structure. m represents 1 or 2; when m is 1, then R 6 represents an aryl group; when m is 2, then R 6 represents an alkylene group, an alkenylene group, or an alkynylene group; and a part of hydrogen atoms of R 4 to R 6 may be substituted with a halogen atom.
  • US4372894A
    申请人:——
    公开号:US4372894A
    公开(公告)日:1983-02-08
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐